These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26504062)

  • 1. Development and Validation of a Novel Plasma Protein Signature for Breast Cancer Diagnosis by Using Multiple Reaction Monitoring-based Mass Spectrometry.
    Lee HB; Kang UB; Moon HG; Lee J; Lee KM; Yi M; Park YS; Lee JW; Yu JH; Choi SH; Cho SH; Lee C; Han W; Noh DY
    Anticancer Res; 2015 Nov; 35(11):6271-9. PubMed ID: 26504062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry.
    Quon BS; Dai DL; Hollander Z; Ng RT; Tebbutt SJ; Man SF; Wilcox PG; Sin DD
    Thorax; 2016 Mar; 71(3):216-22. PubMed ID: 25777587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
    Chen X; Chen H; Dai M; Ai J; Li Y; Mahon B; Dai S; Deng Y
    Oncotarget; 2016 Jun; 7(24):36622-36631. PubMed ID: 27153558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualification and Verification of Serological Biomarker Candidates for Lung Adenocarcinoma by Targeted Mass Spectrometry.
    Wu HY; Goan YG; Chang YH; Yang YF; Chang HJ; Cheng PN; Wu CC; Zgoda VG; Chen YJ; Liao PC
    J Proteome Res; 2015 Aug; 14(8):3039-50. PubMed ID: 26120931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Proteomic Technologies for Blood-Based Detection of Colorectal Cancer.
    Bhardwaj M; Terzer T; Schrotz-King P; Brenner H
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33530402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach.
    Beretov J; Wasinger VC; Millar EK; Schwartz P; Graham PH; Li Y
    PLoS One; 2015; 10(11):e0141876. PubMed ID: 26544852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low abundance protein enrichment for discovery of candidate plasma protein biomarkers for early detection of breast cancer.
    Meng R; Gormley M; Bhat VB; Rosenberg A; Quong AA
    J Proteomics; 2011 Dec; 75(2):366-74. PubMed ID: 21851866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic application of serum protein pattern and artificial neural network software in breast cancer].
    Hu Y; Zhang SZ; Yu JK; Liu J; Zheng S; Hu X
    Ai Zheng; 2005 Jan; 24(1):67-71. PubMed ID: 15642203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteome profiling of breast tumors by gel electrophoresis and nanoscale electrospray ionization mass spectrometry.
    Alldridge L; Metodieva G; Greenwood C; Al-Janabi K; Thwaites L; Sauven P; Metodiev M
    J Proteome Res; 2008 Apr; 7(4):1458-69. PubMed ID: 18257521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Serological Early Biomarker Candidates for Lung Adenocarcinoma by using Multiple Reaction Monitoring-Mass Spectrometry.
    Wu HY; Pan YY; Kopylov AT; Zgoda V; Ma MC; Wang CH; Su WC; Lai WW; Cheng PN; Liao PC
    Proteomics Clin Appl; 2020 Jul; 14(4):e1900095. PubMed ID: 32012456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection.
    Fredolini C; Pathak KV; Paris L; Chapple KM; Tsantilas KA; Rosenow M; Tegeler TJ; Garcia-Mansfield K; Tamburro D; Zhou W; Russo P; Massarut S; Facchiano F; Belluco C; De Maria R; Garaci E; Liotta L; Petricoin EF; Pirrotte P
    Breast Cancer Res; 2020 Dec; 22(1):135. PubMed ID: 33267867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer.
    Whiteaker JR; Zhang H; Zhao L; Wang P; Kelly-Spratt KS; Ivey RG; Piening BD; Feng LC; Kasarda E; Gurley KE; Eng JK; Chodosh LA; Kemp CJ; McIntosh MW; Paulovich AG
    J Proteome Res; 2007 Oct; 6(10):3962-75. PubMed ID: 17711321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic investigation on bio-corona of Au, Ag and Fe nanoparticles for the discovery of triple negative breast cancer serum protein biomarkers.
    Del Pilar Chantada-Vázquez M; López AC; Vence MG; Vázquez-Estévez S; Acea-Nebril B; Calatayud DG; Jardiel T; Bravo SB; Núñez C
    J Proteomics; 2020 Feb; 212():103581. PubMed ID: 31731051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer.
    Yanagisawa K; Tomida S; Shimada Y; Yatabe Y; Mitsudomi T; Takahashi T
    J Natl Cancer Inst; 2007 Jun; 99(11):858-67. PubMed ID: 17551146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma.
    Mangé A; Dimitrakopoulos L; Soosaipillai A; Coopman P; Diamandis EP; Solassol J
    J Proteomics; 2016 Jun; 142():114-21. PubMed ID: 27168011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Validation Study of a Multiple Reaction Monitoring-Based Proteomic Assay to Diagnose Breast Cancer.
    Kim Y; Kang UB; Kim S; Lee HB; Moon HG; Han W; Noh DY
    J Breast Cancer; 2019 Dec; 22(4):579-586. PubMed ID: 31897331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isotope coded protein label quantification of serum proteins--comparison with the label-free LC-MS and validation using the MRM approach.
    Turtoi A; Mazzucchelli GD; De Pauw E
    Talanta; 2010 Feb; 80(4):1487-95. PubMed ID: 20082806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum proteome profiling of primary breast cancer indicates a specific biomarker profile.
    Böhm D; Keller K; Wehrwein N; Lebrecht A; Schmidt M; Kölbl H; Grus FH
    Oncol Rep; 2011 Nov; 26(5):1051-6. PubMed ID: 21837365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
    Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
    J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
    Bonneterre J; Révillion F; Desauw C; Blot E; Kramar A; Fournier C; Hornez L; Peyrat JP
    Oncol Rep; 2013 Jan; 29(1):355-61. PubMed ID: 23117275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.